{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:30:55Z","timestamp":1786336255989,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Chronic hepatitis B virus (HBV) infection is a major issue in North Africa, where HBeAg-negative profiles are predominant. Distinguishing between chronic infection and active chronic hepatitis using conventional markers is sometimes difficult. Our study assessed the correlation of HBsAg with viral load and liver fibrosis, as well as its performance in distinguishing the different evolving phases of chronic HBV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and results<\/jats:title>\n                    <jats:p>\n                      We conducted an analytical cross-sectional study that included 90 HBeAg-negative treatment-na\u00efve patients. All patients underwent biological assessment, HBsAg quantification, viral load, and FibroScan\u00ae. Among the 90 patients (mean age: 47.5\u202f\u00b1\u202f11\u202fyears; 52.6% women), 65.6% were in the low-replicative chronic infection phase. The median viral load was 328.5\u202fIU\/mL, and the median HBsAg level was 213.5\u202fIU\/mL. A strong positive correlation was observed between HBsAg and HBV DNA levels (\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f0.721,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). HBsAg levels showed a weak but significant association with liver fibrosis (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.007, AUC\u202f=\u202f0.631). The performance of HBsAg in differentiating low versus high replicative phases was excellent (AUC\u202f=\u202f0.819;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), with an optimal threshold of 450\u202fIU\/mL (sensitivity: 81.3%; specificity: 77.6%). In multivariate analysis, HBV DNA and AST were independently associated with disease phase, whereas qHBsAg was not an independent predictor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Quantitative HBsAg measurement is a relevant tool for refining the stratification of untreated HBeAg-negative patients as a complementary surrogate marker. When combined with viral load, transaminases, and FibroScan\u00ae, HBsAg could contribute to optimized monitoring and better resource allocation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1857118","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:21:58Z","timestamp":1786335718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative HBsAg as a biomarker for disease staging in untreated chronic hepatitis B patients: a cross-sectional study"],"prefix":"10.3389","volume":"13","author":[{"given":"Soumaya","family":"Mrabet","sequence":"first","affiliation":[{"name":"Gastroenterology Department, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imene","family":"Handous","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Trabelsi","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassmine","family":"Maatouk","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raida","family":"Harbi","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Akkari","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neila","family":"Hannachi","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elhem","family":"Ben Jazia","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospital of Farhat Hached, Faculty of Medicine of Sousse, University of Sousse","place":["Sousse, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"ref1","volume-title":"Global Hepatitis Report 2024","year":"2024"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"15","author":"Grudda","year":"2022","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5009\/gnl230070","article-title":"Quantitative hepatitis B surface antigen, the trustworthy biomarker for functional cure of chronic hepatitis B","volume":"17","author":"Choi","year":"2023","journal-title":"Gut Liver"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3138\/canlivj-2025-0020","article-title":"Hepatitis B virus quantitative surface antigen levels differ by genotype","volume":"8","author":"He","year":"2025","journal-title":"Can Liver J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/1319-3767.182454","article-title":"Are serum quantitative hepatitis B surface antigen levels, liver histopathology and viral loads related in chronic hepatitis B-infected patients?","volume":"22","author":"Balkan","year":"2016","journal-title":"Saudi J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1099\/vir.0.009738-0","article-title":"A novel hepatitis B virus subgenotype, D7, in Tunisian blood donors","volume":"90","author":"Meldal","year":"2009","journal-title":"J Gen Virol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/microorganisms11051101","article-title":"Hepatitis B virus genotype D: an overview of molecular epidemiology, evolutionary history, and clinical characteristics","volume":"11","author":"Sant\u2019Anna","year":"2023","journal-title":"Microorganisms"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"100574","DOI":"10.1016\/j.aohep.2021.100574","article-title":"Hepatitis B virus genotypes and subgenotypes and the natural history and epidemiology of hepatitis B","author":"Reuter","year":"2022","journal-title":"Ann Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/HEP.0000000000000335","article-title":"HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice","volume":"78","author":"Uchida","year":"2023","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3390\/v15122339","article-title":"Core promoter and pre-Core variants of the hepatitis B virus (HBV) are frequent in chronic hepatitis B HBeAg-negative patients infected by genotypes a and D","volume":"15","author":"Reuter","year":"2023","journal-title":"Viruses"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43066-024-00336-5","article-title":"Correlation between quantitative HBsAg and quantitative HBV DNA in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"14","author":"Maimunah","year":"2024","journal-title":"Egypt Liver J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.idnow.2020.10.004","article-title":"The role of quantitative HBsAg in the natural history of e antigen-negative chronic hepatitis B: a Tunisian prospective study","volume":"51","author":"Baklouti","year":"2021","journal-title":"Infect Dis Now"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1128\/JVI.61.4.1108-1115.1987","article-title":"Murine cells carrying integrated tandem genomes of hepatitis B virus DNA transcribe RNAs from endogenous promoters on both viral strands and express middle and major viral envelope proteins","volume":"61","author":"Zelent","year":"1987","journal-title":"J Virol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","article-title":"Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up","volume":"14","author":"Brouwer","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5604\/01.3001.0010.8640","article-title":"Long-term follow-up and quantitative hepatitis B surface antigen monitoring in north American chronic HBV carriers","volume":"17","author":"O\u2019Neil","year":"2018","journal-title":"Ann Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jceh.2015.04.008","article-title":"HBsAg level as predictor of liver fibrosis in HBeAg positive patients with chronic hepatitis B virus infection","volume":"5","author":"Goyal","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"ref20","first-page":"445","article-title":"Association of liver fibrosis based on transient elastography and quantitative HBsAg levels in HBeAg-positive chronic hepatitis B patients","volume":"14","author":"Dhanowar","year":"2024","journal-title":"Eur J Cardiovasc Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"86463","DOI":"10.18632\/oncotarget.21210","article-title":"Serum hepatitis B surface antigen levels predict insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with normal or mildly elevated alanine transaminase levels","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1857118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:22:00Z","timestamp":1786335720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1857118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":21,"alternative-id":["10.3389\/fmed.2026.1857118"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1857118","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1857118"}}